Xeomin (also known as incobotulinum toxin A) is a neuromodulator like Botox and Dysport made by Merz Aesthetics, the same company that makes Radiesse. It has been used in Europe for several years under the name Bocouture and now is FDA approved for treatment of frown lines just like Botox. It is currently used in the United States to treat certain neurological conditions and it is expected to be commercially available for cosmetic use in the United States in 2013. The active component in Xeomin is identical to that in Botox and Dysport, but it lacks what are called accessory proteins. For patients, this means there is a decreased theoretical risk for resistance, but this has not been shown in studies. The results are similar to that of Botox and Dysport: the onset is less than one week and duration of effect is three to four months. The most significant difference is likely to be the cost of the product. The cost has not been released yet, but is likely to be more competitive than that of Botox. This competition will likely drive down the cost of Botox and Dysport, making it more affordable for patients.
No comments:
Post a Comment